[go: up one dir, main page]

WO2006125632A3 - Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy - Google Patents

Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy Download PDF

Info

Publication number
WO2006125632A3
WO2006125632A3 PCT/EP2006/004974 EP2006004974W WO2006125632A3 WO 2006125632 A3 WO2006125632 A3 WO 2006125632A3 EP 2006004974 W EP2006004974 W EP 2006004974W WO 2006125632 A3 WO2006125632 A3 WO 2006125632A3
Authority
WO
WIPO (PCT)
Prior art keywords
adiposity
well
modulate
bind
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/004974
Other languages
French (fr)
Other versions
WO2006125632A2 (en
Inventor
Dieter Link
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RECHTSANWALT DR MARTIN PRAGER ALS INSOLVENZVERWALTER UEBER DAS VERMOEGEN DER XANTOS BIOMEDICINE AG PLUTA RECHTSANWALTS GmbH
RECHTSANWALT DR MARTIN PRAGER
Original Assignee
RECHTSANWALT DR MARTIN PRAGER ALS INSOLVENZVERWALTER UEBER DAS VERMOEGEN DER XANTOS BIOMEDICINE AG PLUTA RECHTSANWALTS GmbH
RECHTSANWALT DR MARTIN PRAGER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05011275A external-priority patent/EP1764109A1/en
Application filed by RECHTSANWALT DR MARTIN PRAGER ALS INSOLVENZVERWALTER UEBER DAS VERMOEGEN DER XANTOS BIOMEDICINE AG PLUTA RECHTSANWALTS GmbH, RECHTSANWALT DR MARTIN PRAGER filed Critical RECHTSANWALT DR MARTIN PRAGER ALS INSOLVENZVERWALTER UEBER DAS VERMOEGEN DER XANTOS BIOMEDICINE AG PLUTA RECHTSANWALTS GmbH
Publication of WO2006125632A2 publication Critical patent/WO2006125632A2/en
Publication of WO2006125632A3 publication Critical patent/WO2006125632A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to agonists of the receptor Fn14 as well as their use for activating the signal pathway of the receptor Fn14 for interfering and/or modulating the differentiation of adipocytes and for use in adiposity/obesity and/or metabolic syndrome. In particular, the invention relates to agonists, preferably antibodies that inhibit the differentiation of pre-adipocytes to mature adipocytes and/or the storage of lipid molecules in differentiating or mature adipocytes by receptor-mediated signal transduction.
PCT/EP2006/004974 2005-05-24 2006-05-24 Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy Ceased WO2006125632A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05011275A EP1764109A1 (en) 2005-05-24 2005-05-24 Agonist antibodies that bind to the TWEAK receptor Fn14, thereby modulating adiposity-associated phenotypes, and their use in therapy
EP05011275.4 2005-05-24
US68991405P 2005-06-13 2005-06-13
US60/689,914 2005-06-13

Publications (2)

Publication Number Publication Date
WO2006125632A2 WO2006125632A2 (en) 2006-11-30
WO2006125632A3 true WO2006125632A3 (en) 2007-02-22

Family

ID=37075587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/004974 Ceased WO2006125632A2 (en) 2005-05-24 2006-05-24 Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy

Country Status (1)

Country Link
WO (1) WO2006125632A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
KR20100053607A (en) * 2007-08-03 2010-05-20 패시트 바이오테크 코포레이션 Therapeutic use of anti-tweak receptor antibodies
BRPI0912198A2 (en) * 2008-05-15 2019-09-24 Biogen Idec Inc anti-fn14 antibodies and uses thereof
BRPI1007529A2 (en) * 2009-01-30 2016-10-18 Biogen Idec Inc methods for pancreatic tissue regeneration
AU2019275733B2 (en) * 2018-05-31 2025-07-31 The Chinese University Of Hong Kong Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities
WO2023232631A1 (en) * 2022-06-01 2023-12-07 Julius-Maximilians-Universität Würzburg Antibody-based soluble and membrane-bound tweak mimicking agonists with fcyr-independent activity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020041876A1 (en) * 1999-12-20 2002-04-11 Wiley Steven R. TWEAK receptor
WO2003086311A2 (en) * 2002-04-09 2003-10-23 Biogen, Inc. Methods for treating tweak-related conditions
WO2004058183A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
WO2005053728A2 (en) * 2003-12-01 2005-06-16 Xantos Biomedicine Ag Obesity-associated proteins and the use thereof in therapy and diagnosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020041876A1 (en) * 1999-12-20 2002-04-11 Wiley Steven R. TWEAK receptor
WO2003086311A2 (en) * 2002-04-09 2003-10-23 Biogen, Inc. Methods for treating tweak-related conditions
WO2004058183A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
WO2005053728A2 (en) * 2003-12-01 2005-06-16 Xantos Biomedicine Ag Obesity-associated proteins and the use thereof in therapy and diagnosis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
M. NAKAYAMA ET AL.: "Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 306, 2003, Duluth, MN, VSA, pages 818 - 825, XP004432093 *
M. NAKAYAMA ET AL.: "Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death.", THE JOURNAL OF IMMUNOLOGY, vol. 170, no. 1, 2003, Baltimore, MD, VSA, pages 341 - 348, XP002356992 *
S. WILEY ET AL.: "A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis.", IMMUNITY, vol. 15, November 2001 (2001-11-01), pages 837 - 846, XP002356991 *
S. WILEY ET AL.: "TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor.", CYTOKINE & GROWTH FACTOR REVIEWS, vol. 14, 2003, pages 241 - 249, XP002356994 *
T. POLEK ET AL.: "TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 34, 22 August 2003 (2003-08-22), Baltimore, MD, VSA, pages 32317 - 32323, XP002356993 *

Also Published As

Publication number Publication date
WO2006125632A2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
EA201001223A1 (en) STABILIZED PROTEIN COMPOSITIONS
WO2008008286A3 (en) Substituted pyrazoles as ghrelin receptor antagonists
MX345226B (en) Formulations of single domain antigen binding molecules.
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2008008887A3 (en) Gpr119 agonists for treating metabolic disorders
Åberg et al. Design, synthesis and evaluation of peptidomimetics based on substituted bicyclic 2-pyridones—Targeting virulence of uropathogenic E. coli
PH12017500954A1 (en) Mutant interleukin-2 polypeptides
WO2008070692A3 (en) Bicyclic compounds and use as antidiabetics
WO2007084841A3 (en) Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
WO2010081679A3 (en) Antibodies against human epo receptor
WO2007106721A3 (en) Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
MY159679A (en) Antibodies binding preferentially human csf1r extracellular domain 4 and their use
WO2008064054A3 (en) Compounds which modulate the cb2 receptor
WO2008119527A3 (en) Agonists of bitter taste receptors and uses thereof
WO2011039510A8 (en) Agents, uses and methods
WO2008064351A3 (en) (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2008020942A3 (en) R-spondin compositions and methods of use thereof
WO2007120689A3 (en) Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
WO2008089022A3 (en) Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
WO2010036630A3 (en) Sulfonyl compounds which selectively modulate the cb2 receptor
WO2007123765A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2007131219A3 (en) Cannabinoid receptor antagonists/inverse agonists
WO2006047417A3 (en) Detection of cannabinoid receptor biomarkers and uses thereof
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
WO2013084151A3 (en) Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06743060

Country of ref document: EP

Kind code of ref document: A2